A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis

“…This would be especially relevant to acellular vaccine-primed individuals, in whom it has been demonstrated that antibodies to pertactin correlated with protection. 42 Through these mechanisms, pertactin deficiency may be amplifying the pertussis disease resurgence, especially in the setting of exclusive use of acellular vaccines that are associated with waning immunity and that fail to prevent B pertussis colonization and transmission. [43][44][45] Because our findings suggest pertussis vaccines remain protective in the setting of high prevalence of pertactin deficiency, other vaccine components (pertussis toxin, filamentous hemagglutinin, or fimbriae) are likely preventing symptomatic pertussis.…”

“…Antibodies against pertussis toxin were shown to correlate modestly with protection in 2 trials, and Denmark has used a mono-component pertussis toxin vaccine for >15 years with an estimated VE of 78%, although this efficacy is now being questioned. 42,[46][47][48] However, data regarding protection elicited by filamentous hemagglutinin or fimbriae-specific immune responses are limited. Because correlates of protection are not well defined for pertussis, it is difficult to determine which vaccine components may be eliciting the necessary immune response.…”

Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience

“…In the logistic regression analyses, there was also a reverse-interaction term between anti-Fim2/3 and anti-PT antibody levels, indicating an antagonism between these two antibodies. Cherry et al have reported similar results [11].…”

Development of improved vaccines against whooping cough: Current status

“…Both wP and aP vaccines confer protection against virulent B. pertussis following immunization. 96,106 In some clinical trials with DTaP, a direct correlation between a serological antibody response and protective immunity could not be verified, 106 whereas in the mouse model the importance of a humoral immune response against pertussis was clearly evident. 34 Nevertheless, it has been accepted, and as will become evident from the description in the text below, that wP and aP vaccines elicit different immune response profiles in humans versus animal models.…”

“…Conway et al 134 evaluated the immunogenicity and protective efficacy of systemically and orally delivered pertussis antigens antibody levels observed following clinical trials of a two-component acellular pertussis vaccine suggested a lack of insight into the true nature of immunity to B. pertussis. 106 Since then many investigations have been carried out using naive and transgenic mouse models to demonstrate the importance of CMI against infection with B. pertussis. Redhead et al 112 observed variable T-cell proliferative responses in mice following convalescent infection or immunization with whole-cell or acellular vaccines.…”